Company profile
THERAPEUTICSMD, INC.
NASDAQ:TXMDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ESTRADIOL | phase3 | — | 21 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02019589 | phase3 | terminated | 2014-01-20 | 2014-10-31 | TherapeuticsMD | A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea |
| NCT01942668 | phase3 | completed | 2013-08-05 | 2016-10-28 | TherapeuticsMD | A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms |
| NCT04290390 | phase1 | completed | 2020-02-12 | 2021-01-06 | TherapeuticsMD | Annovera™ Drug-Drug Interaction Study |
| NCT02253173 | phase3 | completed | 2014-09-01 | 2015-10-01 | TherapeuticsMD | Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women |
| NCT02449902 | phase2 | completed | 2013-07-01 | 2013-09-01 | TherapeuticsMD | TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy |
FDA applications (0)
No records yet.